October 11, 2019
- Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019
September 27, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2019
- Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
September 18, 2019
- Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
September 16, 2019
- Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
September 12, 2019
- Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
September 11, 2019
- Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
September 9, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2019
- Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
August 28, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 82 results
